Synova nets 16.1x return in exit of Kinapse to HgCapital
February 02, 2016
Synova Capital has sold portfolio company Kinapse, a service provider and advisor to the life sciences industry, to HgCapital in a £10 million deal. The sale nets Synova a 16.1x return on total invested capital and an IRR of 126%. The firm had initially backed Kinapse in 2012.